PRTA News and Press, Prothena Corporation plc From 02/23/24

2024-02-23 12:31:39 ET Summary Prothena Corporation plc has an update coming on the phase 1 study using PRX012 for the treatment of patients with Alzheimer's Disease, expected in 2024. Company is already in the process of exploring the use of PRX012 for the treatment of patients w...

2024-02-22 17:44:05 ET More on Prothena Prothena Corporation plc (PRTA) Q4 2023 Earnings Call Transcript Prothena Corporation plc 2023 Q4 - Results - Earnings Call Presentation Prothena: Upcoming Alzheimer's Data Could Solidify Its Position In The Market Prot...

2024-02-21 16:22:42 ET More on Prothena Prothena Corporation plc (PRTA) Q4 2023 Earnings Call Transcript Prothena Corporation plc 2023 Q4 - Results - Earnings Call Presentation Prothena: Upcoming Alzheimer's Data Could Solidify Its Position In The Market Prot...

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today the appointment of Daniel G. Welch to its Board of Directors as an independent director and Chair De...

2024-02-15 23:53:08 ET Prothena Corporation plc (PRTA) Q4 2023 Earnings Conference Call February 15, 2023 4:30 PM ET Company Participants Mark Johnson - Vice President of Investor Relations Gene Kinney - President and Chief Executive Officer Hideki Garren - Chief...

2024-02-15 16:27:16 ET More on Prothena Prothena: Upcoming Alzheimer's Data Could Solidify Its Position In The Market Prothena stock falls as Bank of America downgrades on program delays Prothena stock tumbles 23% in premarket trading Seeking Alpha’s Q...

Net cash used in operating and investing activities was $52.6 million in the fourth quarter and $136.7 million for the full year of 2023; quarter-end cash and restricted cash position was $621.0 million The company expects cash guidance for the full year 2024 net cash used in operating and in...

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its fourth quarter and full year 2023 financial results on Thursday, February 15...

A look at the top 10 most actives in the United States Connexa Sports Technologies Inc. (CNXA) rose 101.2% to $0.4 on volume of 236,162,112 shares PROSHARES TRUST (SQQQ) rose 5.9% to $12.78 on volume of 177,226,563 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 4.5% to $5....

2024-01-30 11:05:09 ET More on Prothena Prothena: Upcoming Alzheimer's Data Could Solidify Its Position In The Market Prothena stock tumbles 23% in premarket trading Seeking Alpha’s Quant Rating on Prothena Historical earnings data for Prothena ...